Sonrotoclax is an investigational new drug that is being evaluated for the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).[1] It is a potent and selective BCL2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.[2]

References

  1. ^ "Sonrotoclax - BeiGene". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Tomkins O, D'Sa S (2024). "Review of BCL2 inhibitors for the treatment of Waldenström's macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma". Frontiers in Oncology. 14: 1490202. doi:10.3389/fonc.2024.1490202. PMC 11570586. PMID 39558954.
Allikas: http://en.wikipedia.org/wiki/Sonrotoclax
No tags for this post.